- Home
- ACRS
as 05-09-2025 4:00pm EST
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | WAYNE |
| Market Cap: | 127.6M | IPO Year: | 2015 |
| Target Price: | $10.67 | AVG Volume (30 days): | 801.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.95 - $5.17 | Next Earning Date: | 05-08-2025 |
| Revenue: | $17,777,000 | Revenue Growth: | -42.87% |
| Revenue Growth (this year): | -71.67% | Revenue Growth (next year): | 425.96% |
Latest Aclaris Therapeutics Inc. News
ACRS Breaking Stock News: Dive into ACRS Ticker-Specific Updates for Smart Investing
GlobeNewswire
14 hours ago
Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series
Zacks
2 days ago
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates
Associated Press Finance
2 days ago
Aclaris: Q1 Earnings Snapshot
GlobeNewswire
2 days ago
Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
MT Newswires
10 days ago
Aclaris Therapeutics Names Jesse Hall Chief Medical Officer
GlobeNewswire
11 days ago
Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer
Simply Wall St.
15 days ago
Strong week for Aclaris Therapeutics (NASDAQ:ACRS) shareholders doesn't alleviate pain of three-year loss
Clinical Trials Arena
17 days ago
Aclaris Therapeutics receives FDA approval for Phase Ia/Ib trial of ATI-052
Compare ACRS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACRS Aclaris Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.